نتائج البحث - "MALT-лимфома"

العلاقة: https://ok.abvpress.ru/jour/article/view/603/420Test; Bestari M.B., Palungkun I.G., Hernowo B.S. et al. Low-Stage Gastric MALT Lymphoma Causing Life-Threatening Upper Gastrointestinal Bleeding. Case Rep Gastroenterol 2019;13(3):376–84. DOI:10.1159/000502795; Swedlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2008.; Baele M., Pasmans F., Flahou B. et al. Non-Helicobacter pylori Helicobacters detected in the stomach of humans comprise several naturally occurring Helicobacter species in animals. FEMS Immunol Med Microbiol 2009;55:306–13. DOI:10.1111/j.1574-695X.2009.00535.x; Achyut B.R., Moorchung N., Srivastava A.N. et al. Risk of lymphoid follicle development in patients with chronic antral gastritis: role of endoscopic features, histopathological parameters, CagA status and interleukin-1 gene polymorphisms. Inflamm Res 2008;57:51–6. DOI:10.1007/s00011-007-7033-2; Малихова О.А. Современная стратегия комплексной эндоскопической диагностики и мониторинг неходжкинских лимфом желудка: дисс. докт. мед. наук. М., 2010. 291 с.; Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диа гностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2021;31(4):70–99. DOI:10.22416/1382-4376-202131-4-70-99; Filip P.V., Cuciureanu D., Diaconu L.D. et al. MALT lymphoma: epidemiology, clinical diagnosis and treatment. J Med Life 2018;11(3):187–93. DOI:10.25122/jml-2018-0035; Ruskoné-Fourmestraux A., Fischbach W., Aleman B.M. et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747–58. DOI:10.1136/gut.2010.224949; Zucca E., Copie-Bergman C., Ricardi U. et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(6): 144–8. DOI:10.1093/annonc/mdt343; Nagtegaal I.D., Odze R.D., Klimstra D. et al. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76(2):182–8. DOI. 10.1111/his.13975; The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:810–43. DOI:10.1016/s00165107(03)02159-x; Нейроэндокринные опухоли. Общие принципы диагностики и лечения: практическое руководство / Под ред. проф. В.А. Горбуновой. М.: ГЭОТАР-Медиа, 2021. 600 с. DOI:10.33029/9704-5997-3-NEU-2021-1-600; Chin J.L., O’Toole D. Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clin Endosc 2017;50(6):520–9. DOI:10.5946/ce.2017.181; Chung C.S., Tsai C.L., Chu Y.Y. et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Tawian (DEST). Medicine (Baltimore) 2018;97(38):e12101. DOI:10.1097/MD.0000000000012101; Гордеев С.С., Магаррамова З.Н., Мышляков В.С. и др. Редкие злокачественные новообразования в практике онкопроктолога: ретроспективный анализ опыта клиники за 20 лет. Поволжский онкологический вестник 2023;13(4):31–7. DOI:10.32000/2078-1466-2022-4-31-37; Гордеев С.С. Роль химиолучевой терапии в лечении нейроэндокринного рака прямой кишки: серия клинических наблюдений. Сибирский онкологический журнал 2022;21(4):90–7.; https://ok.abvpress.ru/jour/article/view/603Test

الإتاحة: https://doi.org/10.17650/2686-9594-2023-13-2-27-37Test
https://doi.org/10.1159/000502795Test
https://doi.org/10.1111/j.1574-695X.2009.00535.xTest
https://doi.org/10.1007/s00011-007-7033-2Test
https://doi.org/10.22416/1382-4376-202131-4-70-99Test
https://doi.org/10.25122/jml-2018-0035Test
https://doi.org/10.1136/gut.2010.224949Test
https://doi.org/10.1093/annonc/mdt343Test
https://doi.org/10.1016/s00165107Test(03)02159-x
https://doi.org/10.33029/9704-5997-3-NEU-2021-1-600Test

View record in BASE

4

دورية أكاديمية

Association of IRF5 (rs2004640), STAT4 (rs7574865), and TNFAIP3 (rs6920220, rs2230926) gene polymorphisms with primary Sjögren's syndrome and its complication, MALT-lymphoma ; Взаимосвязь полиморфизмов генов IRF5 (rs2004640), STAT4 (rs7574865) и TNFAIP3 (rs6920220, rs2230926) с синдромом Шегрена и его осложнением – MALT-лимфомой

المؤلفون: I. A. Guseva, A. V. Torgashina, J. I. Khvan, M. Yu. Krylov, E. Yu. Samarkina, N. V. Konovalova, D. A. Varlamov, И. А. Гусева, А. В. Торгашина, Ю. И. Хван, М. Ю. Крылов, Е. Ю. Самаркина, Н. В. Коновалова, Д. А. Варламов

المساهمون: The investigation has been conducted within the framework of government task scientific topic № 1021051402790-6. The investigation has not been sponsored, Статья подготовлена в рамках государственного задания по теме № 1021051402790-6. Исследование не имело спонсорской поддержки

المصدر: Modern Rheumatology Journal; Том 17, № 5 (2023); 29-35 ; Современная ревматология; Том 17, № 5 (2023); 29-35 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: IRF5 rs2004640, Sjögren's syndrome, MALT-lymphoma, leucopenia, genetic polymorphisms, STAT4 rs7574865, TNFAIP3 rs6920220, TNFAIP3 rs2230926, синдром Шегрена, MALT-лимфома, лейкопения, генетические полиморфизмы

وصف الملف: application/pdf

العلاقة: https://mrj.ima-press.net/mrj/article/view/1473/1392Test; Сафонова ТН, Васильев ВИ, Лихванцева ВГ. Синдром Шегрена: Руководство для врачей. Москва: Московский государственный университет имени М.В.Ломоносова; 2013. 600 с.; Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med. 2022 Feb;22(1):9-25. doi:10.1007/s10238-021-00728-6.; Васильев ВИ, Пробатова НА, Тупицын НН и др. MALT-лимфомы при болезни Шегрена. Терапевтический архив. 2006;78(1):45-52.; Zintzaras E, Voulgarelis M, Moutsopoulos HM, et al. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005 Nov 14;165(20): 2337-44. doi:10.1001/archinte.165.20.2337.; Johnsen SJ, Brun JG, Gøransson LG, et al. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken). 2013 May;65(5): 816-21. doi:10.1002/acr.21887.; Nezos A, Mavragani CP. Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis. J Immunol Res. 2015;2015:754825. doi:10.1155/2015/754825. Epub 2015 Oct 15.; Björk A, Mofors J, Wahren-Herlenius M, et al. Environmental factors in the pathogenesis of primary Sjögren's syndrome. J Intern Med. 2020 May;287(5):475-492. doi:10.1111/joim.13032.; Bombardieri M, Argyropoulou OD, Ferro F, et al. One year in review 2020: pathogenesis of primary Sjögren's syndrome. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):3-9.; Thorlacius GE, Björk A, Wahren-Herlenius M, et al. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023 May; 19(5):288-306. doi:10.1038/s41584-023-00932-6.; Reveille JD, Wilson RW, Provost TT, et al. Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. Ann Intern Med. 1984 Dec;101(6):748-56. doi:10.7326/0003-4819-101-6-748.; Kuo CF, Grainge MJ, Valdes AM, et al. Familial Risk of Sjögren's Syndrome and Co-aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study. Arthritis Rheumatol. 2015 Jul;67(7):1904-12. doi:10.1002/art.39127.; Gershwin ME, Terasaki PI, Graw R, Chused TM. Increased frequency of HL-A8 in Sjögren's syndrome. Tissue Antigens. 1975 Nov;6(5):342-6. doi:10.1111/j.1399-0039.1975.tb00653.x.; Chused TM, Kassan SS, Opelz G. Sjögren's syndrome associated with HLA Dw3. N Engl J Med. 1977 Apr 21;296(16): 895-7. doi:10.1056/NEJM197704212961602.; Teos LY, Alevizos I. Genetics of Sjögren's syndrome. Clin Immunol. 2017 Sep;182:41-47. doi:10.1016/j.clim.2017.04.018.; Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet. 2013 Nov;45(11):1284-92. doi:10.1038/ng.2792.; Harris VM, Scofield RH, Sivils KL, et al. Genetics in Sjögren's syndrome: where we are and where we go. Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):234-239.; Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017 Jan;76(1):9-16. doi:10.1136/annrheumdis-2016-210571.; Гусева ИА, Демидова НВ, Сорока НЕ и др. Исследование полиморфизмов генов-кандидатов иммунного ответа как маркеров риска развития ревматоидного артрита и продукции аутоантител. Научно-практическая ревматология. 2016: 54(1);21-30.; Eriksson P, Brun JG, Wang C, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes Immun. 2009 Jan;10(1):68-76. doi:10.1038/gene.2008.94.; Korman BD, Alba MI, Le JM, et al. Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun. 2008 Apr;9(3):267-70. doi:10.1038/gene.2008.1.; Li H, Ice JA, Lessard CJ, Sivils KL. Interferons in Sjögren's Syndrome: Genes, Mechanisms, and Effects. Front Immunol. 2013 Sep 20;4:290. doi:10.3389/fimmu.2013.00290.; Takaoka A, Yanai H, Kondo S, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature. 2005 Mar 10;434(7030):243-9. doi:10.1038/nature03308.; Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004 Dec;202:139-56. doi:10.1111/j.0105-2896.2004.00211.x.; Kaplan MH. STAT4: a critical regulator of inflammation in vivo. Immunol Res. 2005; 31(3):231-42. doi:10.1385/IR:31:3:231.; Palomino-Morales RJ, Diaz-Gallo LM, Witte T, et al. Influence of STAT4 polymorphism in primary Sjögren’s syndrome. J Rheumatol. 2010 May;37(5):1016-9. doi:10.3899/jrheum.091007. Epub 2010 Apr 1.; Gestermann N, Mekinian A, Comets E, et al. STAT4 is a confirmed genetic risk factor for Sjögren’s syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun. 2010 Jul;11(5):432-8. doi:10.1038/gene.2010.29. Epub 2010 Jun 10.; Colafrancesco S, Ciccacci C, Priori R, et al. STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjögren's Syndrome: Association with Disease Susceptibility and Clinical Aspects. J Immunol Res. 2019 Feb 10; 2019:7682827. doi:10.1155/2019/7682827.; Miceli-Richard C, Comets E, Loiseau P, et al. Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum. 2007 Dec;56(12):3989-94. doi:10.1002/art.23142.; Ciccacci C, Latini A, Perricone C, et al. TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjögren Syndrome-Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients. J Immunol Res. 2019 Aug 27;2019:6728694. doi:10.1155/2019/6728694.; Khatri B, Tessneer KL, Rasmussen A, et al. Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells. Nat Commun. 2022 Jul 27;13(1):4287. doi:10.1038/s41467-022-30773-y.; Nezos A, Gkioka E, Koutsilieris M, et al. TNFAIP3 F127C Coding Variation in Greek Primary Sjögren's Syndrome Patients. J Immunol Res. 2018 Dec 19;2018:6923213. doi:10.1155/2018/6923213.; Nocturne G, Tarn J, Boudaoud S, et al. Germline variation of TNFAIP3 in primary Sjögren’s syndrome-associated lymphoma. Ann Rheum Dis. 2016 Apr;75(4):780-3. doi:10.1136/annrheumdis-2015-207731. Epub 2015 Sep 2.; Velissari A, Vassilakopoulos TP, Angelopoulou MK, et al. Genetic polymorphisms and risk of MALT lymphoma in Greek population. Curr Res Transl Med. 2022 May;70(2):103330. doi:10.1016/j.retram.2021.103330.; Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009 Aug;30(8):383-91. doi:10.1016/j.it.2009.05.007. Epub 2009 Jul 28.; Zhang M, Peng LL, Wang Y, et al. Roles of A20 in autoimmune diseases. Immunol Res. 2016 Apr;64(2):337-44. doi:10.1007/s12026-015-8677-6.; Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science. 2000 Sep 29;289(5488):2350-4. doi:10.1126/science.289.5488.2350.; https://mrj.ima-press.net/mrj/article/view/1473Test

الإتاحة: https://doi.org/10.14412/1996-7012-2023-5-29-35Test
https://doi.org/10.1007/s10238-021-00728-6Test
https://doi.org/10.1001/archinte.165.20.2337Test
https://doi.org/10.1002/acr.21887Test
https://doi.org/10.1155/2015/754825Test
https://doi.org/10.1111/joim.13032Test
https://doi.org/10.1038/s41584-023-00932-6Test
https://doi.org/10.7326/0003-4819-101-6-748Test
https://doi.org/10.1002/art.39127Test
https://doi.org/10.1111/j.1399-0039.1975.tb00653.xTest